Last reviewed · How we verify
NCT06673225
INSPIRE Respiratory Health Program in Botucatu, São Paulo, Brazil
trial testing Analysis of results in Community Health Services in 2,000 participants. Currently enrolling.
15 April 2029
Quick facts
| Lead sponsor | UPECLIN HC FM Botucatu Unesp |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 16 April 2024 |
| Primary completion | 15 April 2029 |
| Estimated completion | 1 December 2029 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Analysis of results
Conditions studied
- Community Health Services — all drugs for Community Health Services →
- Respiratory Disease — all drugs for Respiratory Disease →
- Tobacco Smoking — all drugs for Tobacco Smoking →
Sponsor
UPECLIN HC FM Botucatu Unesp — full company profile →
Who can join
18 and older, any sex, with Community Health Services or Respiratory Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to evaluate the implementation of the INSPIRE program and to plan actions for the preparation, coordination, monitoring, diagnosis, and treatment of respiratory diseases in the municipality of Botucatu. Methods: Individuals with respiratory symptoms from the municipality of Botucatu, aged 18 or older, will be invited to participate in the study, and socioeconomic data, as well as information on sex, gender, race, nutritional risk, frailty, tobacco exposure, and its derivatives, will be collected. For those with exposure, screening and treatment for respiratory diseases will be offered through assessment of pulmonary function, body composition, respiratory and peripheral muscle strength. Additionally, individuals over 40 years old with tobacco exposure equal to or greater than 30 pack-years will be offered low-dose chest CT screening for lung cancer. Expected results: To identify and assess vulnerable groups that face difficulties in accessing respiratory healthcare, as well as implement specific strategies for the treatment of respiratory diseases and tobacco control for these groups. To ensure equitable access to respiratory health for the entire population at risk due to smoking. Moreover, through proactive and reactive risk reduction actions implemented by the program, to intervene in distinct groups and other regions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06673225
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other UPECLIN HC FM Botucatu Unesp trials
Trials by the same sponsor.
- NCT06326203 — Cell Therapy for Lower Limb Ulcers in Patients With Critical Limb Ischemia · Phase 1, PHASE2 · not yet recruiting
- NCT06214429 — Shear Wave Elastography for Carotid Atherosclerotic Plaques · recruiting
- NCT04937543 — Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19 · Phase 2 · completed
- NCT04743011 — Enriched Heparin Anti COVID-19 Trial · Phase 1, PHASE2 · completed
- NCT05860439 — Lower Limb Sclerotherapy of Reticular Veins and Telangiectasias · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06673225 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by UPECLIN HC FM Botucatu Unesp
- Last refreshed: 4 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06673225.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing